{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T20:28:50Z","timestamp":1786739330502,"version":"build-2736575974"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:p>Tofacitinib, an oral Janus kinase (JAK) inhibitor, has established efficacy in the management of several autoimmune and inflammatory disorders, including rheumatoid arthritis, psoriatic arthritis, dermatitis, and ulcerative colitis. By inhibiting JAK phosphorylation, tofacitinib modulates cytokine-mediated inflammatory responses through interference with the JAK-STAT signaling pathway. In recent years, accumulating real-world evidence from India has suggested a beneficial role for tofacitinib in the management of ocular inflammatory diseases, particularly in patients with refractory disease who have failed conventional disease-modifying antirheumatic drugs and biologic therapies. Factors such as oral administration, rapid clinical response, ease of monitoring, and relative affordability compared with biologics have facilitated its wider adoption in routine clinical practice in the Indian setting. This review discusses the drug tofacitinib, mode of action, safety profile, its utility in non-infectious uveitis and with a particular emphasis on real-world data and socioeconomic considerations relevant to resource-limited settings.<\/jats:p>","DOI":"10.4103\/ijo.ijo_46_26","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T05:00:24Z","timestamp":1779858024000},"page":"845-850","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Tofacitinib: New drug in the therapeutic armamentarium in ocular inflammation"],"prefix":"10.4103","volume":"74","author":[{"given":"Kalpana","family":"Babu","sequence":"first","affiliation":[{"name":"Department of Uvea and Ocular Inflammation, Prabha Eye Clinic and Research Centre and Vittala International Institute of Ophthalmology, Bengaluru, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vidya","family":"Mooss","sequence":"additional","affiliation":[{"name":"Department of Uvea and Ocular Inflammation, Prabha Eye Clinic and Research Centre and Vittala International Institute of Ophthalmology, Bengaluru, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,5,27]]},"reference":[{"key":"R1-20260527","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ajoc.2018.12.001","article-title":"Tofacitinib for refractory uveitis and scleritis","volume":"13","author":"Paley","year":"2019","journal-title":"Am J Ophthalmol Case Rep"},{"key":"R2-20260527","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s10067-019-04875-w","article-title":"JAK inhibitors in refractory juvenile idiopathic arthritis-associated uveitis","volume":"39","author":"Miserocchi","year":"2020","journal-title":"Clin Rheumatol"},{"key":"R3-20260527","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41433-025-04065-w","article-title":"The use of Janus kinase inhibitors to treat noninfectious uveitis","volume":"40","author":"Beckman","year":"2026","journal-title":"Eye (Lond)"},{"key":"R4-20260527","doi-asserted-by":"crossref","first-page":"9","DOI":"10.7365\/JHPOR.2021.1.2","article-title":"Cost per responder analysis of biologics in moderate-to-severe plaque psoriasis in Indian healthcare setting","volume":"1","author":"Gokhale","year":"2021","journal-title":"J Health Policy Outcomes Res"},{"key":"R5-20260527","doi-asserted-by":"crossref","first-page":"420","DOI":"10.4103\/idoj.idoj_665_24","article-title":"A real-world study of tofacitinib in Indian patients with refractory moderate-to-severe atopic dermatitis, its economic considerations and immunological rationale","volume":"16","author":"Sardana","year":"2025","journal-title":"Indian Dermatol Online J"},{"key":"R6-20260527","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.3390\/pharmaceutics14051001","article-title":"A comprehensive overview of globally approved JAK inhibitors","volume":"14","author":"Shawky","year":"2022","journal-title":"Pharmaceutics"},{"key":"R7-20260527","doi-asserted-by":"crossref","first-page":"930071","DOI":"10.3389\/fmed.2022.930071","article-title":"Effectiveness and safety of JAK inhibitors in autoinflammatory diseases: A Systematic review","volume":"9","author":"Boyadzhieva","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"R8-20260527","first-page":"318","article-title":"The mechanism of action of tofacitinib-An oral Janus kinase inhibitor for the treatment of rheumatoid arthritis","volume":"34","author":"Hodge","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"R9-20260527","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1124\/dmd.113.054940","article-title":"The pharmacokinetics, metabolism, and clearance mechanisms of tofacitinib, a janus kinase inhibitor, in humans","volume":"42","author":"Dowty","year":"2014","journal-title":"Drug Metab Dispos"},{"key":"R10-20260527","doi-asserted-by":"crossref","first-page":"1756284819848631","DOI":"10.1177\/1756284819848631","article-title":"Tofacitinib in the treatment of ulcerative colitis: Efficacy and safety from clinical trials to real-world experience","volume":"12","author":"D\u2019Amico","year":"2019","journal-title":"Ther Adv Gastroenterol"},{"key":"R11-20260527","doi-asserted-by":"crossref","first-page":"911","DOI":"10.4103\/ijo.IJO_789_22","article-title":"Tofacitinib in juvenile idiopathic arthritis-associated uveitis","volume":"2","author":"Babu","year":"2022","journal-title":"Indian J Ophthalmol Case Rep"},{"key":"R12-20260527","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1080\/09273948.2025.2532828","article-title":"Tofacitinib in ocular inflammation: Experience from a tertiary eye centre in South India","volume":"33","author":"Babu","year":"2025","journal-title":"Ocul Immunol Inflamm"},{"key":"R13-20260527","doi-asserted-by":"crossref","first-page":"101104","DOI":"10.1016\/j.ajoc.2021.101104","article-title":"Tofacitinib for refractory ocular mucous membrane pemphigoid","volume":"22","author":"James","year":"2021","journal-title":"Am J Ophthalmol Case Rep"},{"key":"R14-20260527","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/j.ophtha.2012.01.028","article-title":"Tofacitinib (CP-690,550), a Janus kinase inhibitor for dry eye disease: Results from a phase 1\/2 trial","volume":"119","author":"Liew","year":"2012","journal-title":"Ophthalmology"},{"key":"R15-20260527","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1080\/09273948.2024.2323671","article-title":"Tofacitinib for refractory uveitis and scleritis in children: A case series","volume":"32","author":"Dutta Majumder","year":"2024","journal-title":"Ocul Immunol Inflamm"},{"key":"R16-20260527","doi-asserted-by":"crossref","first-page":"367","DOI":"10.31138\/mjr.20230828.ti","article-title":"Tofacitinib in refractory scleritis: A case series","volume":"34","author":"Dey","year":"2023","journal-title":"Mediterr J Rheumatol"},{"key":"R17-20260527","doi-asserted-by":"crossref","first-page":"784860","DOI":"10.3389\/fphar.2021.784860","article-title":"Case Report: A promising treatment strategy for noninfectious uveitis","volume":"12","author":"Liu","year":"2021","journal-title":"Front Pharmacol"},{"key":"R18-20260527","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1080\/09273948.2022.2113805","article-title":"Tofacitinib in scleritis: A case series","volume":"32","author":"Pyare","year":"2024","journal-title":"Ocul Immunol Inflamm"},{"key":"R19-20260527","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.4103\/ijo.IJO_534_20","article-title":"Tofacitinib in recalcitrant scleritis: First case report from India","volume":"68","author":"Pyare","year":"2020","journal-title":"Indian J Ophthalmol"},{"key":"R20-20260527","doi-asserted-by":"crossref","first-page":"8294560","DOI":"10.1155\/2020\/8294560","article-title":"New potential weapons for refractory scleritis in the era of targeted therapy","volume":"2020","author":"Fabiani","year":"2020","journal-title":"Mediators Inflamm"},{"key":"R21-20260527","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1080\/09273948.2019.1605453","article-title":"Effect of Janus Kinase inhibitor treatment on anterior uveitis and associated macular edema in an adult patient with juvenile idiopathic arthritis","volume":"27","author":"Bauermann","year":"2019","journal-title":"Ocul Immunol Inflamm"},{"key":"R22-20260527","first-page":"403452","article-title":"Tofacitinib citrate for ulcerative keratitis in a patient with rheumatoid arthritis","volume":"2014","author":"Meadow","year":"2014","journal-title":"Case Rep Rheumatol"},{"key":"R23-20260527","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1136\/annrheumdis-2016-210457","article-title":"Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: Integrated analysis of data from the global clinical trials","volume":"76","author":"Cohen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R24-20260527","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0140-6736(12)61424-X","article-title":"Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: A randomised phase 3 trial","volume":"381","author":"Burmester","year":"2013","journal-title":"Lancet"},{"key":"R25-20260527","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1056\/NEJMoa1310476","article-title":"Tofacitinib versus methotrexate in rheumatoid arthritis","volume":"370","author":"Lee","year":"2014","journal-title":"N Engl J Med"},{"key":"R26-20260527","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1056\/NEJMoa1112072","article-title":"Tofacitinib or adalimumab versus placebo in rheumatoid arthritis","volume":"367","author":"van Vollenhoven","year":"2012","journal-title":"N Engl J Med"},{"key":"R27-20260527","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa1109071","article-title":"Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis","volume":"367","author":"Fleischmann","year":"2012","journal-title":"N Engl J Med"},{"key":"R28-20260527","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1002\/art.40803","article-title":"Tofacitinib in combination with methotrexate in patients with rheumatoid arthritis: Clinical efficacy, radiographic, and safety outcomes from a twenty-four-month, phase III study","volume":"71","author":"van der Heijde","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"R29-20260527","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1002\/art.38745","article-title":"Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis","volume":"66","author":"Winthrop","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"R30-20260527","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1136\/annrheumdis-2021-221915","article-title":"Tofacitinib and risk of cardiovascular outcomes: Results from the Safety of TofAcitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study","volume":"81","author":"Khosrow-Khavar","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"R32-20260527","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"key":"R34-20260527","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.semarthrit.2016.05.014","article-title":"Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor","volume":"46","author":"Charles-Schoeman","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"R35-20260527","doi-asserted-by":"crossref","first-page":"e482","DOI":"10.1097\/RHU.0000000000001552","article-title":"Incidence rates of interstitial lung disease events in tofacitinib-treated rheumatoid arthritis patients: Post hoc analysis from 21 clinical trials","volume":"27","author":"Citera","year":"2021","journal-title":"J Clin Rheumatol"},{"key":"R36-20260527","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1136\/annrheumdis-2014-205847","article-title":"Tofacitinib, an oral Janus kinase inhibitor: Analysis of malignancies across the rheumatoid arthritis clinical development programme","volume":"75","author":"Curtis","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"R37-20260527","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1080\/09273948.2025.2450472","article-title":"Economic burden and cost-effectiveness of management of non-infectious uveitis: A systematic review","volume":"33","author":"Sriranganathan","year":"2025","journal-title":"Ocul Immunol Inflamm"},{"key":"R38-20260527","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta23150","article-title":"Adalimumab in combination with methotrexate for refractory uveitis associated with juvenile idiopathic arthritis: A RCT","volume":"23","author":"Ramanan","year":"2019","journal-title":"Health Technol Assess"},{"key":"R39-20260527","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1136\/bjophthalmol-2018-312756","article-title":"Adalimumab for non-infectious uveitis: Is it cost-effective?","volume":"103","author":"Bermejo","year":"2019","journal-title":"Br J Ophthalmol"},{"key":"R40-20260527","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.mayocp.2023.08.029","article-title":"Real-world clinical equivalence of generic and branded tofacitinib: A prospective longitudinal cohort study in patients with rheumatoid arthritis","volume":"99","author":"Zhao","year":"2024","journal-title":"Mayo Clin Proc"},{"key":"R41-20260527","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1007\/s10067-022-06205-z","article-title":"Real-world evidence of the effectiveness and safety of generic tofacitinib in rheumatoid arthritis patients: A retrospective, single-centre analysis from Western India","volume":"41","author":"Phatak","year":"2022","journal-title":"Clin Rheumatol"}],"container-title":["Indian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_46_26","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T19:28:04Z","timestamp":1786735684000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_46_26"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,27]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/ijo.ijo_46_26","relation":{},"ISSN":["0301-4738","1998-3689"],"issn-type":[{"value":"0301-4738","type":"print"},{"value":"1998-3689","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,27]]},"assertion":[{"value":"2026-01-04","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-05","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}